BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2023.
World J Clin Cases. Jan 6, 2023; 11(1): 104-115
Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.104
Table 1 Socio-demographics variables of participants (N = 262)
VariableNPercentage (%)
Gender
Female14153.8
Male12146.2
Age (mo)1
1-2410340.2
25-489135.5
49 and above6224.2
Screened for tuberculosis2
Yes24895.4
No124.6
Diagnosed to have tuberculosis3
Yes00
No260100.0
Type of Facility
Private for profit17366.0
Private not for profit8934.0
Table 2 Treatment monitoring

Variable
N
Percentage (%)
Commenced on isoniazidYes262100.0
1st mo WT (kg)1-7 238.8
8-1517065.4
16-23 6625.4
24-31 10.4
1st mo Dose< 100 mg10640.5
150-200 mg15358.4
250 mg and above31.1
2nd mo WT (kg)1-72311.4
8-1512260.4
16-235627.7
24-3110.5
2nd mo Dose< 100 mg8741.4
150-200 mg12157.6
250 mg and above21.0
3rd mo WT (kg)1-7157.9
8-1510555.3
16-236936.3
24-3110.5
3rd mo Dose< 100 mg7539.9
150-200 mg11159.0
250 mg and above21.1
4th mo WT (kg)1-7127.3
8-159255.8
16-235734.5
24-3142.4
4th mo Dose< 100 mg6738.5
150-200 mg10660.9
250 mg and above10.6
5th mo WT (kg)1-7106.3
8-159157.2
16-235333.3
24-3153.1
5th mo Dose< 100 mg6238.3
150-200 mg9961.1
250 mg and above10.6
6th mo WT (kg)1-764.1
8-157954.1
16-235638.4
24-3153.4
6th mo Dose< 100 mg5535.5
150-200 mg9963.9
250 mg and above10.6
Table 3 Determinant of treatment outcome, n (%)
Treatment Outcome
Completed
Loss to follow up
Total
χ2
DF
P value
GenderMale88 (33.6)53 (20.2)141 (53.8)1.33610.248
Female67 (25.6)54 (20.6)121 (46.2)
Total155 (59.2)107 (40.8)262 (100.0)
Age0-2457 (55.3)46 (44.7)103 (40.2)4.11420.128
25-4862 (68.1)29 (31.9)91 (35.5)
49 and above34 (54.8)28 (45.2)62 (24.2)
Total153 (59.8)103 (40.2)256 (100.0)
Type of facilityPFP103 (39.3)70 (26.7)173 (66.0)0.03010.862
PNFP52 (19.8)37 (14.1)89 (34.0)
Total155 (59.2)107 (40.8)262 (100.0)


Write to the Help Desk